Tempus Launches Its First Study With a Nonprofit Foundation Collaborator to Create Robust FL Dataset This multi-year study will enroll FL patients to generate a comprehensive, multi-omic dataset using ...
Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Subcutaneous time-limited mosunetuzumab exhibited “highly encouraging efficacy” among patients with ...
2025 OCT 03 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News-- A new study on Oncology - Follicular Lymphoma is now available. According to news reporting from Duluth, ...
Patients receiving the tafasitamab combination achieved a median PFS of 22.4 months, compared with 13.9 months for patients receiving placebo with lenalidomide and rituximab. This represents a 57% ...
Please provide your email address to receive an email when new articles are posted on . Most patients in the high-risk study population had some response to treatment. All high-grade treatment-related ...
Graphical abstract of the research findings, including key features of the three subtypes C1, C2 and C3.Graphical abstract of the research findings, including key features of the three subtypes C1, C2 ...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and ...
Tempus Launches Its First Study With a Nonprofit Foundation Collaborator to Create Robust FL Dataset Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results